Hyderabad first. APAC nodes later.
BioHelix is a working name for a possible future Singapore or Southeast Asia node. Programmable Bio does not currently operate a Singapore lab and does not claim a signed MiRXES partnership.
Replicate a proven cell, not an untested blueprint
The right time to add another geography is after the Hyderabad cell has repeatable customer demand, stable methods, measurable utilization, and a documented quality system. A new node should copy a working operating unit while adding capabilities that the home site cannot provide efficiently.
Regional customer access
Shorter logistics and stronger commercial coverage for Southeast Asian academic, biotech, and pharma teams.
Regulatory and manufacturing ecosystem
Potential access to Singapore's translational research, diagnostics, and advanced-manufacturing networks.
Capacity resilience
A second qualified node can absorb demand and reduce reliance on one physical site.
Method portability
LabOS should make a validated method reproducible across compatible cells, instruments, and operators.
What must be true before expansion
Hyderabad unit economics
Demonstrated utilization, reproducibility, turnaround, demand, and gross-margin performance.
Customer pull
Named APAC customers or partners whose needs justify local execution rather than a prestige address.
Signed operating partner or owned-site plan
Defined responsibilities, quality system, IP terms, regulatory scope, and economics.
Portable methods
Evidence that LabOS protocols and data contracts transfer without degrading assay performance.
The current moat is execution. A Singapore entity or partnership becomes useful only when it makes the operating network better.